TUNAR: A Potential Drug Target and Biomarker (G100507043)

Target Name: TUNAR

NCBI ID: G100507043

TUNAR

TUNAR: A Potential Drug Target and Biomarker

Tunar is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In recent years, researchers have been investigating the potential drug targets of Tunar, with a focus on its role as a biomarker for disease.

One of the key challenges in studying Tunar is its complex structure. Tunar is a transmembrane protein that is composed of four distinct regions: an extracellular region, a transmembrane region, an intracellular region, and an N-end region. The extracellular region consists of a long, flexible tail that is involved in Tunar's interactions with other proteins, while the transmembrane region is responsible for the protein's ability to span the cell membrane. The intracellular region contains the protein's active site, where Tunar functions as a regulator of cell growth and differentiation.

While the structure of Tunar has posed some challenges, researchers have made significant progress in understanding its function. One of the most significant findings of recent years was the identification of a Tunar-deficient mouse model that was resistant to cancer. This mouse model provided researchers with a valuable tool for studying the role of Tunar in cancer development and progression.

In addition to its potential as a cancer drug target, Tunar has also been investigated for its role as a biomarker for disease. The ability of Tunar to be expressed and processed in the liver makes it an attractive candidate for use as a liver biomarker. Researchers have used a variety of techniques to demonstrate that Tunar is expressed in the liver, and have shown that it is able to be detected using techniques such as qRT-PCR and Western blotting.

Another potential application of Tunar as a biomarker is its ability to be modified and used to monitor the effectiveness of drugs. This is because Tunar is highly modifiable, and has been shown to be able to be targeted to specific cellular processes using various techniques such as genetic modification and small molecule inhibition. This allows researchers to use Tunar as a biomarker to monitor the effectiveness of drugs in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, Tunar is a protein that has the potential to be a drug target and biomarker. Its complex structure and its ability to be modified make it an attractive candidate for both research and clinical applications. Further research is needed to fully understand the role of Tunar in disease, and to determine its potential as a drug and biomarker.

Protein Name: TCL1 Upstream Neural Differentiation-associated RNA

Functions: In neurons, plays a role in the regulation of intracellular Ca(2+), possibly by acting as an activator of ATP2A2/SERCA2, thus increasing the efficiency with which Ca(2+) is removed from the cytoplasm (By similarity). Inhibits differentiation of embryonic stem cells into neurons and inhibits neurite outgrowth, likely as a result of its role in intracellular Ca(2+) regulation (By similarity). In pancreatic beta cells, lowers Ca(2+) levels in the endoplasmic reticulum and enhances glucose-stimulated insulin secretion (PubMed:34513312)

The "TUNAR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TUNAR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets